Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (191)
  2. Journal Article (123)
  3. Review (21)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
  8. Miscellaneous (1)
Groups
  1. Adult Leukemia (351)
  2. Center for Hematologic Malignancies (351)
  3. Department of Medicine (351)
  4. Hematologic Malignancies, Division of (351)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (15)
  2. 2024 (35)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (148)
  2. Journal of Clinical Oncology (18)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (164)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (22)
  4. American Society of Clinical Oncology (18)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
    Journal Article

    Li, B.; An, W.; Wang, H.; Baslan, T.; Mowla, S.; Krishnan, A.; Xiao, W.; Koche, R. P.; Liu, Y.; Cai, S. F.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
    Journal Article

    Mascarenhas, J.; Kosiorek, H. E.; Prchal, J. T.; Rambaldi, A.; Berenzon, D.; Yacoub, A.; Harrison, C. N.; McMullin, M. F.; Vannucchi, A. M.; Ewing, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine
    Journal Article

    Gigoux, M.; Holmström, M. O.; Zappasodi, R.; Park, J. J.; Pourpe, S.; Bozkus, C. C.; Mangarin, L. M. B.; Redmond, D.; Verma, S.; Schad, S.; more...
    Science Translational Medicine (2022)

    Fulltext@MSK | Save
  • Exploratory analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
    Meeting Abstract

    Harrison, C.; Verstovsek, S.; Salama, M. E.; Mascarenhas, J.; Talpaz, M.; Mesa, R.; Vannucchi, A. M.; Rampal, R. K.; Oh, S.; Olteanu, H.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis - Update of clinical and translational data from the ongoing MANIFEST trial
    Meeting Abstract

    Curto-Garcia, N.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Vannucchi, A. M.; Verstovsek, S.; Harrison, C.; Bose, P.; Schiller, G. J.; Rampal, R.; more...
    British Journal of Haematology (2022)

    Fulltext@MSK | Save
  • Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phase
    Journal Article

    Wang, X.; Rampal, R. K.; Hu, C. S.; Tripodi, J.; Farnoud, N.; Petersen, B.; Rossi, M. R.; Patel, M.; McGovern, E.; Najfeld, V.; more...
    JCI Insight (2022)

    Fulltext@MSK | Save
  • Conventional interferon-a 2b versus hydroxyurea for newly-diagnosed patients with polycythemia vera in a real world setting: A retrospective study based on 286 patients from a single center
    Research Letter

    Liu, D.; Xu, Z.; Zhang, P.; Qin, T.; Sun, X.; Qu, S.; Pan, L.; Ma, J.; Cai, W.; Liu, J.; more...
    Haematologica (2022)

    Fulltext@MSK | Save
  • Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
    Research Letter

    King, A. C.; Weis, T. M.; Derkach, A.; Ball, S.; Pandey, M.; Mauro, M. J.; Goldberg, A. D.; Stahl, M.; Famulare, C.; Tallman, M. S.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Disease-modifying potential of bet inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis - preliminary Data
    Meeting Abstract

    Verstovsek, S.; Salama, M. E.; Mascarenhas, J.; Talpaz, M.; Mesa, R. A.; Vannucchi, A.; Rampal, R.; Oh, S. T.; Olteanu, H.; Chiu, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of cusatuzumab in combination with venetoclax and azacitidine (CVA) in patients with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy; An open-label, multicenter, phase 1b study
    Meeting Abstract

    Roboz, G. J.; Pabst, T.; Aribi, A.; Brandwein, J. M.; Döhner, H.; Fiedler, W.; Gandini, D.; Geddes, M.; Hou, J. Z.; Howes, A. J.; more...
    Blood (2021)

    Fulltext@MSK | Save